Business Wire

MI-UPSTREAM-SECURITY

Share
Upstream Security Receives Investment from Cisco Investments as the Demand for IoT Cybersecurity Soars

Upstream Security, a leading provider of cybersecurity extended detection and response (XDR) for connected vehicles and IoT, today announced it received an investment from Cisco Investments. The proliferation of complex IoT devices in the Mobility, Automotive, and Transportation sectors introduces unprecedented operational efficiencies, data-driven services and solutions, and exceptional customer experience. However, advanced connectivity and software-defined components also open the door for large-scale cyber risks, threatening business availability and data integrity.

Upstream already protects millions of mobility connected vehicles and IoT devices worldwide, offering a cloud-based multi-layered approach to extended detection and response.

“We are thrilled to welcome Cisco Investments to our group of investors,” states Yoav Levy, Upstream Security Co-founder and CEO. “This investment provides a unique opportunity to deepen our impact on the IoT sector, and more specifically Mobility, Automotive and Transportation.”

This investment by Cisco Investments amplifies the need for purpose-built IoT cybersecurity solutions that will safeguard the mobility and IoT ecosystem across the entire development and production lifecycle.

“Together with our partners, Cisco is enabling automobile manufacturers across the globe to provide mission-critical, secure connectivity as cars transform into data centers on wheels," says Cisco Investments vice president, Aleem Rizvon. “With an expected 95% of new vehicles having embedded connectivity by the year 2030, we can also expect a rise in automotive cybersecurity threats. Investing in solutions, to ensure the right safeguards for secure connectivity and operation are in place, is critical to instill the trust needed for wide adoption of the technology, not just in the automotive segment, but more broadly for other IoT applications, as well.

Disrupting the IoT Cybersecurity Landscape

Upstream’s cloud-based IoT XDR platform analyzes, in real-time, the contextual state of physical IoT assets and their connected ecosystem, to holistically identify and mitigate cyber risks. The Platform is agentless, requiring no installation of software or hardware, enabling rapid deployment and comprehensive coverage of devices already in production.

The Platform ingests, parses, and normalizes vast amounts of connected vehicle data, IoT protocols, telematics, API transactions, and other data streams from tens of millions of devices, endpoints, and application consumers. This data enables the creation of unique digital twins—near real-time representations of devices and endpoints, facilitating holistic and effective detection. By monitoring devices, services, and overall asset behavior, the Platform detects both known and unknown anomalies based on proprietary ML-powered models.

Coupled with a purpose-built vehicle security operation center (vSOC), dedicated for monitoring and investigating connected vehicles and IoT cyber threats, Upstream provides a holistic suite of cybersecurity solutions and services to enable customers to proactively identify and remediate cyber threats. Utilizing Upstream’s Ocean AI, Generative AI-powered capabilities, accelerates the investigation remediation process.

About Upstream Security

Upstream provides a cloud-based data management platform purpose-built for mobility and IoT, delivering unparalleled cybersecurity extended detection and response (XDR) and data-driven applications. The Upstream Platform secures more than 25 million connected vehicles and IoT devices and is trusted by large vehicle manufacturers and IoT service providers.

Upstream recently published its 2024 Automotive Cybersecurity Report, providing a detailed analysis of the cyber landscape across the Automotive and Mobility ecosystem, emerging risks, and the evolving regulatory landscape.

www.upstream.auto

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240410994590/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Dompé Doses First Patients in Europe and US in Phase 3 Studyof Isocyclosporin for Atopic Keratoconjunctivitis16.12.2025 13:00:00 CET | Press release

Atopic keratoconjunctivitis(AKC) is a chronic inflammatory disease of the eye that is frequently associated with atopic conditions, and limited disease awareness often leads to delayed or missed diagnosis. Isocyclosporin is a novel, dual inhibitor oftwo critical immunepathways in ocular inflammation like AKC. Dompé, a leading biopharmaceutical company with operations in Italy and the U.S., announced the first patients have been enrolled in a Phase 3 study of Isocyclosporin for the treatment of atopic keratoconjunctivitis (AKC). Isocyclosporin is a dual inhibitor of transient receptor potential (TRP) cation channel, mucolipin subfamily, member 2 (TRPML2) and calcineurin, key regulators of immune and inflammatory response in chronic inflammatory eye diseases. The Phase 3 trial is a multicenter, randomized, double-masked study comparing isocyclosporin against vehicle control in improving ocular signs and symptoms after six weeks of treatment. “This milestone underscores Dompé’s commitment

Visa Launches Stablecoin Settlement in the United States, Marking a Breakthrough for Stablecoin Integration16.12.2025 13:00:00 CET | Press release

With more than $3.5B in annualized stablecoin settlement volume1, Visa brings USDC settlement to U.S. institutions. Visa Inc. (V) today announced the launch of USDC settlement in the United States, marking a major milestone in the company’s stablecoin settlement pilot program and strategy to modernize its settlement layer underpinning global commerce. For the first time, U.S. issuer and acquirer partners can settle with Visa in Circle’s USDC, a fully reserved, dollar-denominated stablecoin. With USDC settlement, issuers can benefit from faster funds movement over blockchains, seven‑day availability and enhanced operational resilience across weekends and holidays - without any change to the consumer card experience. Initial banking participants include Cross River Bank and Lead Bank, which have started settling with Visa in USDC over the Solana blockchain. Broader availability in the U.S. is planned through 2026. Additionally, Visa is a design partner for Arc, a new Layer 1 blockchain d

Volante Technologies Customers Successfully Navigate Critical Regulatory Deadlines for EU SEPA Instant and Global SWIFT Cross-Border Payments16.12.2025 10:00:00 CET | Press release

PaaS leader ensures seamless migrations and uninterrupted payment operations Volante Technologies, the global leader in Payments as a Service (PaaS), today announced it has successfully upgraded its clients to meet the latest SEPA Instant Payments Regulation (IPR) and SWIFT SRG 2025 mandate, which came into effect October 9th and November 22nd, 2025, respectively. This announcement follows the major FedISO upgrade in July, which shifted trillions of dollars in payments to the new ISO 20022 messaging format. SEPA IPR is a significant European milestone, requiring payments to be made within 10 seconds and at any time of day, throughout the year. Adoption was mandatory and Eurozone banks were compelled to meet strict deadlines, with January 9th, 2025 the deadline for receiving incoming instant payments and October 9th the deadline for sending outgoing instant payments. The latest deadline impacted more than 700 banks across Europe, with non-compliance penalties reaching at least 10% of an

TreeFrog Therapeutics Announces Changes to Executive Committee With the Arrival of Mark Rothera as Chief Executive Officer & Board Member to Spearhead Next Phase of Growth16.12.2025 09:05:00 CET | Press release

TreeFrog Therapeutics, a French biotech focused on bringing regenerative medicine to millions through their proprietary cell technology, C-Stem™ is delighted to announce the appointment of skilled biotech leader, Mark Rothera, as Chief Executive Officer and Board member. He succeeds Frédéric Desdouits, who is stepping down after five years in the role. In the new leadership configuration, co-founders Kévin Alessandri and Maxime Feyeux will transition from daily operations to focus on their roles on the Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251215145193/en/ Mark Rothera, CEO TreeFrog Therapeutics Elsy Boglioli, Chair of the Board of TreeFrog Therapeutics, commented “On behalf of the Board, we are delighted to welcome Mark to TreeFrog. His 30+ years of biopharma leadership, including most recently, three biotech CEO roles in gene therapy and biologics, will be invaluable as we advance our Parkinson’s and liver

RoslinCT and Ayrmid Ltd. Announce Expansion of Strategic Partnership to Manufacture Omisirge® (omidubicel-onlv) for Second FDA-Approved Indication in Severe Aplastic Anemia (SAA)16.12.2025 09:00:00 CET | Press release

RoslinCT is performing technology transfer and will support commercial manufacture of Omisirge® for an additional indication following successful clinical trialsOmisirge® now FDA-approved for an expanded patient population in hematologyRoslinCT continues to support and advance multiple cell therapy projects at its Hopkinton, MA facility Ayrmid Ltd., the parent company of Gamida Cell Inc., a pioneering cell therapy company transforming cells into powerful therapeutics, and RoslinCT, a global leader in cell and gene therapy contract development and manufacturing, today announced the expansion of their strategic partnership to include the execution of a commercial supply agreement to support production of Omisirge® (omidubicel-onlv). Following positive clinical trial results, Omisirge® has received FDA approval for a second indication, broadening its use in the treatment of hematology patients. Under the commercial supply agreement, RoslinCT will complete technology transfer and support c

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye